留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码
x

亚临床甲状腺功能亢进症与心血管疾病关系的研究进展

张琴,  陈隽

downloadPDF
文章导航 > 分子影像学杂志  > 2016 >  39(4): 443-446
张琴, 陈隽. 亚临床甲状腺功能亢进症与心血管疾病关系的研究进展[J]. 分子影像学杂志, 2016, 39(4): 443-446.
引用本文: 张琴, 陈隽. 亚临床甲状腺功能亢进症与心血管疾病关系的研究进展[J]. 分子影像学杂志, 2016, 39(4): 443-446.
shu
Qin ZHANG, Jun CHEN. Research progress of the relationship between subclinical hyperthyroidism and cardiovascular disease[J]. Journal of Molecular Imaging, 2016, 39(4): 443-446.
Citation: Qin ZHANG, Jun CHEN. Research progress of the relationship between subclinical hyperthyroidism and cardiovascular disease[J]. Journal of Molecular Imaging, 2016, 39(4): 443-446.
shu

亚临床甲状腺功能亢进症与心血管疾病关系的研究进展

  • 重庆医科大学附属第二医院内分泌科，重庆 400010

详细信息
    作者简介:

    张琴，硕士，E-mail: 941887272@qq.com

    通讯作者:

    陈隽，主任医师，教授，硕士生导师，E-mail: 2080557950@qq.com

Research progress of the relationship between subclinical hyperthyroidism and cardiovascular disease

  • Endocrinology Department, The Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China

    摘要
  • 摘要: 亚临床甲状腺功能亢进症是指促甲状腺激素低于正常范围，而甲状腺激素在正常范围的一类疾病。亚临床甲亢被认为是处于健康及临床甲亢的中间状态，是否可导致心血管事件的发生风险增加，以及是否需要筛查及积极干预治疗，既往相关研究结果，结论不一；近来研究表明亚临床甲状腺亢进症与心血管疾病的发生、发展与不利转归密切相关，本文就亚临床甲状腺功能亢进症与心血管疾病关系的研究进展作一综述。

     

    Abstract: Subclinical hyperthyroidism was defined as a serum thyrotropin (TSH) concen-tration below the nomal range with normal levels of thyroid hormones, which was considered to be an intermediate state between health and clinical hyperthyroidism.Whether subclinical hyperthyroidism increased the risk of cardiovascular disease and should be screened and actively treated, results of the previous relevant researches remain controversial. Recent studies showed that subclinical hyperthyroidism was significantly associated with higher risk of cardiovascular disease and cardiovascular mor-tality. We reviewed the research development of the relationship between subclinical hyperthyroidism and cardiovascular disease.

     

    • HTML全文
    • 参考文献(29)
  • [1] Klein I, Danzi S. Thyroid disease and the heart[J]. Circulation, 2007, 116(15): 1725-35. doi: 10.1161/CIRCULATIONAHA.106.678326
    [2] Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T (4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES Ⅲ)[J]. J Clin Endocrinol Metab, 2002, 87(2): 489-99. doi: 10.1210/jcem.87.2.8182
    [3] Cappola AR, Fried LP, Arndd AM, et al. Thyroid status, Cardio-Vascular risk, and mortality in older adults: the cardiovascular HealthStudy[J]. JAMA, 2006, 295(9): 1033-41. doi: 10.1001/jama.295.9.1033
    [4] Laurberg P, Cerqueira C, Ovesen L, et al. Iodine intake as a determinant of thyroid disorders in populations[J]. Best Pract Res Clin Endocrinol Metab, 2010, 24(1): 13-27. doi: 10.1016/j.beem.2009.08.013
    [5] Somwaru LL, Arnold AM, Joshi N, et al. High frequency of and factors associated with thyroid hormone over-replacement and under-replacement in men and women aged 65 and over[J]. J Clin Endocrinol Metab, 2009, 94(4): 1342-5. doi: 10.1210/jc.2008-1696
    [6] Cooper DS, Biondi B. Subclinical thyroid disease[J]. Lancet, 2012, 379(9821): 1142-54. doi: 10.1016/S0140-6736(11)60276-6
    [7] Sgarbi JA, Villaça FG, Garbeline B, et al. The effects of early antithyroid thera-py for Endogenous subclinical hyperthyroidism in clinical and heart abnormal-lities[J]. J Clin Endocrinol Metab, 2003, 88(4): 1672-7. doi: 10.1210/jc.2002-021046
    [8] Biondi B, Palmieri EA, Fazio S, et al. Endogenous subclinical hyperthyroidism affects quality of Life and cardiac morphology and function in young and middle-aged patients[J]. J Clin Endocrinol Metab, 2000, 85(12): 4701-5. http://www.ncbi.nlm.nih.gov/pubmed/11134131
    [9] Maratou E, Hadjidakis DJ, Peppa MA, et al. Studies of insulin resistance in patients with clinical and subclinical hyperthyroidism [J]. Eur J Endocrinol, 2010, 163(4): 625-30. https://www.ncbi.nlm.nih.gov/pubmed/19141606
    [10] Yavuz DG, Yüksel M, Deyneli O, et al. Association of serum paraoxonase activity with insulin sensitivity and oxidative stress in hyperthyroid and TSH-suppressed nodular goitre patients[J]. Clin Endocrinol (Oxf), 2004, 61(4): 515-21. doi: 10.1111/cen.2004.61.issue-4
    [11] Roos A, Bakker SJ, Links TP, et al. Thyroid function is associated with components of the metabolic syndrome in euthyroid subjects [J]. J Clin Endocrinol Metab, 2007, 92(2): 491-6. doi: 10.1210/jc.2006-1718
    [12] Yang LB, Jiang DQ, Qi WB, et al. Subclinical hyperthyroidism and the risk of cardiovascular events and all-cause mortality: an updated meta-analysis of cohort studies[J]. Eur J Endocrinol, 2012, 167(1): 75-84. doi: 10.1530/EJE-12-0015
    [13] Klein I, Ojamaa K. Thyroid hormone and the cardiovascuclar system [J]. N Engl J Med, 2001, 344(7): 501-9. doi: 10.1056/NEJM200102153440707
    [14] Gencer B, Collet TH, Virgini V, et al. Subclinical thyroid dysfunction and the risk of heart failure events: an individual participant data analysis from 6 prospective cohorts[J]. Circulation, 2012, 126(9): 1040-9. doi: 10.1161/CIRCULATIONAHA.112.096024
    [15] Pearce EN, Yang Q, Benjamin EJ, et al. Thyroid function and left ventricular structure and function in the Framingham Heart Study [J]. Thyroid, 2010, 20(4): 369-73. doi: 10.1089/thy.2009.0272
    [16] Selmer C, Olesen JB, Hansen ML, et al. Subclinical and overt thyroid dysfunction and risk of all-cause mortality and cardiovascular events: a large population study[J]. J Clin Endocrinol Metab, 2014, 99(7): 2372-82. doi: 10.1210/jc.2013-4184
    [17] Selmer C, Olesen JB, Hansen ML, et al. The spectrum of thyroid disease and risk of new onset atrial fibrillation: a large population cohort study[J]. BMJ, 2012, 345(7): e7895-9. https://www.ncbi.nlm.nih.gov/pubmed/23186910
    [18] Parle JV, Maisonneuve P, Sheppard MC, et al. Prediction of all-cause and cardiovascular mortality in elderly People from one low serum thyrotropin result: a 10-year cohort study[J]. Lancet, 2001, 358(9285): 861-5. doi: 10.1016/S0140-6736(01)06067-6
    [19] Collet TH, Gussekloo J, Bauer DC, et al. Subclinical hyperthyroidism and the risk of coronary heart disease and mortality[J]. Arch Intern Med, 2012, 172(10): 799-809. https://www.ncbi.nlm.nih.gov/pubmed/22529182
    [20] Kita PA, Siewko K, Telejko B, et al. The changes in the endothelial function and haemostatic and inflammatory parameters in subclinical and overthyperthyroidism[J]. Int J Endocrinol, 2013, 13(5): 981638-45. https://www.ncbi.nlm.nih.gov/pubmed/24367378
    [21] Erem C, Civan N, Coskun H, et al. Signal peptide-CUB-EGF domain-containing protein 1(SCUBE1)levels in patients with overt and subclinical hyperthyroidism:effects of treatment[J]. Clin Endocrinol(Oxf), 2015, 16(9): 458-63. http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fcen.12955
    [22] Coban E, Aydemir M, Yazicioglu G, et al. Endothelial dysfunction in subjects with subclinical hyperthyroidism[J]. J Endocrinol Invest, 2006, 29(3): 197-200. doi: 10.1007/BF03345539
    [23] Coban E, Aydemir M. Levels of plasma fibrinogen and D-dimer in subjects with subclinical hyperthyroidism[J]. Med Sci Monit, 2008, 14(1): CR42-6. https://www.ncbi.nlm.nih.gov/pubmed/18160944
    [24] Erem C, Kocak M, Nuhoglu I, et al. Blood coagulation, fibrinolysis and lipid profile in patients with prolactinoma[J]. Clin Endocrinol (Oxf), 2010, 73(4): 502-7. https://www.ncbi.nlm.nih.gov/pubmed/20039901
    [25] Singh S, Duggal J, Molnar J, et al. Impact of subclinical thyroid disorders on coronary heart disease, cardiovascular and all-cause mortality: a meta-analysis[J]. Int J Cardiol, 2008, 125(1): 41-8. doi: 10.1016/j.ijcard.2007.02.027
    [26] Vadiveloo T, Donnan PT, Cochrane L, et al. The thyroid epidemiology, audit, and research study (TEARS): morbidity in patients with endogenous subclinical hyperthyroidism[J]. J Clin Endocrinol Metab, 2011, 96(5): 1344-51. doi: 10.1210/jc.2010-2693
    [27] Faber J, Wiinberg N, Schifter S, et al. Haemodynamic changes following treatment of subclinical and overt hyperthyroidism[J]. Eur J Endocrinol, 2001, 145(4): 391-6. doi: 10.1530/eje.0.1450391
    [28] Kaminski G, Michalkiewicz D, Makowski K, et al. Prospective echo-cardiographic evaluation of patients with endogenous subclinicalhyperthyroidism and after restoring euthyroidism[J]. Clin Endocrinol (Oxf), 2011, 74(4): 501-7. doi: 10.1111/cen.2011.74.issue-4
    [29] Sgarbi JA, Villaça FG, Garbeline B, et al. The effects of early antithyroid therapy for endogenous subclinical hyperthyroidism in clinical and heart abnormalities[J]. J Clin Endocrinol Metab, 2003, 88(4): 1672-7. doi: 10.1210/jc.2002-021046
    • 相关文章
    • 施引文献
  • 资源附件(0)
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  1083
  • HTML全文浏览量:  341
  • PDF下载量:  2
  • 被引次数: 0
出版历程
  • 收稿日期:  2016-10-07
  • 刊出日期:  2016-04-01

目录

    /

    返回文章
    返回
    • 版权所有© 2013《分子影像学杂志》编辑部 ICP备00000000号
    • 重点提示: Adobe Reader6可能造成全文显示不正常，请升级为Adobe Reader7或更高。
    • 地址: 广东省广州市广州大道北1838号 Tel: 020-61648176 E-mail: 

    本系统由 北京仁和汇智信息技术有限公司 开发  技术支持：info@rhhz.net

    x 关闭 永久关闭

    关于《分子影像学杂志》变更刊期通知

    各位专家、作者、读者：

    为了缩短出版时滞，促进科研成果的快速传播，我刊自2024年1月起，刊期由双月刊变更为月刊。本刊主要栏目有：基础研究、临床研究、技术方法、综述等。

    感谢各位专家、作者、读者长期以来对我刊的支持与厚爱！

    南方医科大学学报编辑部

    《分子影像学杂志》

    2023年12月27日